Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline.
Kazuyuki TobeHideki SuganamiKohei KakuPublished in: Journal of diabetes investigation (2017)
Although tofogliflozin was effective regardless of baseline insulin level, it showed the highest efficacy in the H group.